Carbamazepine extended-release capsules in bipolar disorder
نویسنده
چکیده
Carbamazepine (CBZ) has long been a therapeutic option for bipolar disorder. Carbamazepine extended-release capsules (CBZ-ERC) are a recent formulation of CBZ approved by the US Food and Drug Administration in 2004 for the treatment of acute manic and mixed episodes associated with bipolar I disorder. This new formulation was developed to improve dosing convenience and decrease daily fluctuations in serum CBZ concentration, thereby lowering the incidence of adverse events. Two randomized, double-blind, placebo-controlled trials and an open-label extension study have demonstrated that CBZ-ERC monotherapy is efficacious in patients with bipolar I disorder experiencing either manic or mixed episodes. In these trials, CBZ-ERC was shown to be a safe and well-tolerated therapy. Retrospective chart reviews conducted in private practice settings have shown that clinical response to CBZ-ERC is independent of bipolar subtype, as patients with bipolar I depression and bipolar II disorder responded similarly to patients with bipolar I disorder either manic or mixed episodes. CBZ is currently considered a treatment alternative to lithium and valproate according to the American Psychiatric Association's treatment guidelines for patients with bipolar disorder. Although further study is required, the clinical evidence presented in these studies may change the treatment paradigm.
منابع مشابه
Long-term Treatment of Bipolar Disorder with Carbamazepine Extended-Release Capsules in Adults, Adolescents, and Children
Bipolar disorder is a serious, lifelong illness that affects approximately 5.7 million American adults, or approximately 2.6% of the US population 18 years of age and over in a given year. The median age of onset is 25 years. It is a complex illness characterized by mania, depression, or mixed episodes, and rapid cycling. Diagnosis and treatment are often complicated by the presence of a variet...
متن کاملDesign and Optimization of Novel Sugar Alcohol Based Extended Release Tablets Prepared by Melt Dispersion Technique
The aim of this study is to prepare novel sorbitol based extended release tablets by melt dispersion method using carbamazepine as a model drug. Carbamazepine was melted along with sugar alcohol to get melt dispersion granules (MGDs) and was characterized by differential scanning calorimetry (DSC), powder X-ray diffractometry (XRD) and solubility study. The physical and chemical parameters...
متن کاملAcute hypersensitivity syndrome caused by valproic Acid: a review of the literature and a case report.
Valproic acid (VPA) is an antiepileptic medication used in the treatment of bipolar disorder. Its toxicity profile is characterized by a very rare but well-documented complication-hepatotoxicity. The risk of acute hypersensitivity syndrome (AHS) caused by VPA is less well known. In the vast majority of reported cases of AHS, the syndrome is the result of aromatic anticonvulsants (AAs), such as ...
متن کاملLong-term treatment of bipolar disorder
Bipolar disorder is characterised by recurrent episodes of mania and depression. The major objective of long term treatment is to reduce the frequency of these episodes. Lithium is the most widely recommended drug for this purpose, having been shown in controlled clinical trials to be more effective than placebo in reducing the likelihood of relapse. Unfortunately, its effectiveness in clinical...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Neuropsychiatric Disease and Treatment
دوره 2 شماره
صفحات -
تاریخ انتشار 2006